New therapeutic targets in transfusion-dependent and-independent thalassemia

被引:41
作者
Cappellini, M. Domenica [1 ,2 ]
Motta, Irene [1 ]
机构
[1] Ca Granda Policlinico, Fdn IRCCS, Milan, Italy
[2] Univ Milan, Dept Clin Sci & Community Hlth, Milan, Italy
关键词
FETAL-HEMOGLOBIN; INEFFECTIVE ERYTHROPOIESIS; BETA-THALASSEMIA; CLINICAL-TRIALS; OPEN-LABEL; IRON; HEPCIDIN; DISEASE; ACE-011; GLOBIN;
D O I
10.1182/asheducation-2017.1.278
中图分类号
G40 [教育学];
学科分类号
040101 ; 120403 ;
摘要
beta-Thalassemas are characterized by reduced production of beta-globin chain, resulting in alpha/beta-chain unbalance and precipitation of alpha-globin-heme complexes and determining ineffective erythropoiesis. Ineffective erythropoesis, chronic hemolytic anemia, and compensatory hematopoietic expansion are the disease hallmarks, and they are related to the severity of the chain unbalance. Several clinical forrns of beta-thalassemia, including the coinheritance of beta-thalassemia with hemoglobin E resulting in hemoglobin E/beta-thalassemia, have been described. Clinically, beta-thalassemias can be classified as transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT) according to the severity of the phenotype, which is caused by a wide spectrum of mutations in a homozygous or compound heterozygous state. Current treatment of TDT consists of regular transfusions that lead to iron overload, requiring iron chelation to prevent iron-related organ toxicity. NTDT patients do not require transfusions or only occasionally require them; however, they develop iron overload as well because of increased intestinal iron absorption caused by chronic anemia. Hematopoietic stem cell allogenic transplant is the only approved cure for beta-thalassemia; however, it is still lirnited by clinical conditions and the availability of matched donors as well as by potential graft-versus-host disease (GVHD). Gene therapy could avoid the GVHD risk, although hematopoietic stem cells must be genetically modified ex vivo. Epigenetic manipulation and genomic editing are novel experimental approaches. An increased understanding of the pathophysiology that controls the disease process prompted us to explore alternative therapeutic approaches that address the underlying chain unbalance, ineffective erythropoiesis, and iron dysregulation. Molecules, such as JAK2 inhibitors and the activin-receptor ligand trap that target ineffective erythropoiesis, are already in clinical trials with promising results. Other agents aimed to generate iron-restricted erythropoiesis are also under experimental evaluation.
引用
收藏
页码:278 / 283
页数:6
相关论文
共 41 条
[1]   Transplantation in thalassemia: Revisiting the Pesaro risk factors 25 years later [J].
Angelucci, Emanuele ;
Pilo, Federica ;
Coates, Thomas D. .
AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (05) :411-413
[2]  
AYDINOK Y, 2016, BLOOD, V128
[3]   Haploinsufficiency for the erythroid transcription factor KLF1 causes hereditary persistence of fetal hemoglobin [J].
Borg, Joseph ;
Papadopoulos, Petros ;
Georgitsi, Marianthi ;
Gutierrez, Laura ;
Grech, Godfrey ;
Fanis, Pavlos ;
Phylactides, Marios ;
Verkerk, Annemieke J. M. H. ;
van der Spek, Peter J. ;
Scerri, Christian A. ;
Cassar, Wilhelmina ;
Galdies, Ruth ;
van IJcken, Wilfred ;
Ozgur, Zeliha ;
Gillemans, Nynke ;
Hou, Jun ;
Bugeja, Marisa ;
Grosveld, Frank G. ;
von Lindern, Marieke ;
Felice, Alex E. ;
Patrinos, George P. ;
Philipsen, Sjaak .
NATURE GENETICS, 2010, 42 (09) :801-U100
[4]   Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers [J].
Breda, Laura ;
Motta, Irene ;
Lourenco, Silvia ;
Gemmo, Chiara ;
Deng, Wulan ;
Rupon, Jeremy W. ;
Abdulmalik, Osheiza Y. ;
Manwani, Deepa ;
Blobel, Gerd A. ;
Rivella, Stefano .
BLOOD, 2016, 128 (08) :1139-1143
[5]   The mutual control of iron and erythropoiesis [J].
Camaschella, C. ;
Pagani, A. ;
Nai, A. ;
Silvestri, L. .
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 :20-26
[6]  
Cappellini MD, 2015, HAEMATOLOGICA, V100, P17
[7]  
Cappellini M-D., 2014, Guidelines for the management of transfusion dependent thalassaemia (TDT)
[8]   Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera [J].
Casu, Carla ;
Oikonomidou, Paraskevi Rea ;
Chen, Huiyong ;
Nandi, Vijay ;
Ginzburg, Yelena ;
Prasad, Princy ;
Fleming, Robert E. ;
Shah, Yatrik M. ;
Valore, Erika V. ;
Nemeth, Elizabeta ;
Ganz, Tomas ;
MacDonald, Brian ;
Rivella, Stefano .
BLOOD, 2016, 128 (02) :265-276
[9]   Gene Therapy for β-Hemoglobinopathies [J].
Cavazzana, Marina ;
Antoniani, Chiara ;
Miccio, Annarita .
MOLECULAR THERAPY, 2017, 25 (05) :1142-1154
[10]   Reactivation of Developmentally Silenced Globin Genes by Forced Chromatin Looping [J].
Deng, Wulan ;
Rupon, Jeremy W. ;
Krivega, Ivan ;
Breda, Laura ;
Motta, Irene ;
Jahn, Kristen S. ;
Reik, Andreas ;
Gregory, Philip D. ;
Rivella, Stefano ;
Dean, Ann ;
Blobel, Gerd A. .
CELL, 2014, 158 (04) :849-860